TY - JOUR A1 - Putra, Sulistyo Emantoko Dwi A1 - Neuber, Corinna A1 - Reichetzeder, Christoph A1 - Hocher, Berthold A1 - Kleuser, Burkhard T1 - Analysis of genomic DNA methylation levels in human placenta using liquid Chromatography-Electrospray ionization tandem mass spectrometry JF - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology N2 - Background: DNA-methylation is a common epigenetic tool which plays a crucial role in gene regulation and is essential for cell differentiation and embryonic development. The placenta is an important organ where gene activity can be regulated by epigenetic DNA modifications, including DNA methylation. This is of interest as, the placenta is the interface between the fetus and its environment, the mother. Exposure to environmental toxins and nutrition during pregnancy may alter DNA methylation of the placenta and subsequently placental function and as a result the phenotype of the offspring. The aim of this study was to develop a reliable method to quantify DNA methylation in large clinical studies. This will be a tool to analyze the degree of DNA methylation in the human placenta in relationship to clinical readouts. Methods: Liquid chromatography-electrospray ionization/multi-stage mass spectrometry (LC-ESI/MS/MS) technique was used for the quantification of the 5dmC/dG ratio in placentas from 248 healthy pregnancies. We were able to demonstrate that this method is a reliable and stable way to determine global placental DNA methylation in large clinical trials. Results/Conclusion: The degree of placental DNA methylation seen in our pilot study varies substantially from 2% to 5%. The clinical implications of this variation need to be demonstrated in adequately powered large studies. KW - Pregnancy KW - Placenta KW - Methylation KW - Global KW - LC-MS/MS KW - Fetal programming KW - Clinical Y1 - 2014 U6 - https://doi.org/10.1159/000358666 SN - 1015-8987 SN - 1421-9778 VL - 33 IS - 4 SP - 945 EP - 952 PB - Karger CY - Basel ER - TY - JOUR A1 - Fayyaz, Susann A1 - Japtok, Lukasz A1 - Kleuser, Burkhard T1 - Divergent role of sphingosine 1-Phosphate on insulin resistance JF - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology N2 - Insulin resistance is a complex metabolic disorder in which insulin-sensitive tissues fail to respond to the physiological action of insulin. There is a strong correlation of insulin resistance and the development of type 2 diabetes both reaching epidemic proportions. Dysfunctional lipid metabolism is a hallmark of insulin resistance and a risk factor for several cardiovascular and metabolic disorders. Numerous studies in humans and rodents have shown that insulin resistance is associated with elevations of non-esterified fatty acids (NEFA) in the plasma. Moreover, bioactive lipid intermediates such as diacylglycerol (DAG) and ceramides appear to accumulate in response to NEFA, which may interact with insulin signaling. However, recent work has also indicated that sphingosine 1-phosphate (S1P), a breakdown product of ceramide, modulate insulin signaling in different cell types. In this review, we summarize the current state of knowledge about S1P and insulin signaling in insulin sensitive cells. A specific focus is put on the action of S1P on hepatocytes, pancreatic beta-cells and skeletal muscle cells. In particular, modulation of S1P-signaling can be considered as a potential therapeutic target for the treatment of insulin resistance and type 2 diabetes. KW - Sphingosine 1-phosphate (S1P) KW - Insulin resistance KW - Ceramides KW - Diacylglycerol (DAG) KW - Non-esterified fatty acids (NEFA) KW - Hepatocytes KW - Pancreatic cells KW - Skeletal muscle cells Y1 - 2014 U6 - https://doi.org/10.1159/000362990 SN - 1015-8987 SN - 1421-9778 VL - 34 IS - 1 SP - 134 EP - 147 PB - Karger CY - Basel ER - TY - JOUR A1 - Arlt, Olga A1 - Schwiebs, Anja A1 - Japtok, Lukasz A1 - Rueger, Katja A1 - Katzy, Elisabeth A1 - Kleuser, Burkhard A1 - Radeke, Heinfried H. T1 - Sphingosine-1-Phosphate modulates dendritic cell function: focus on non-migratory effects in vitro and in vivo JF - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology N2 - Dendritic cells (DCs) are the cutting edge in innate and adaptive immunity. The major functions of these antigen presenting cells are the capture, endosomal processing and presentation of antigens, providing them an exclusive ability to provoke adaptive immune responses and to induce and control tolerance. Immature DCs capture and process antigens, migrate towards secondary lymphoid organs where they present antigens to naive T cells in a well synchronized sequence of procedures referred to as maturation. Indeed, recent research indicated that sphingolipids are modulators of essential steps in DC homeostasis. It has been recognized that sphingolipids not only modulate the development of DC subtypes from precursor cells but also influence functional activities of DCs such as antigen capture, and cytokine profiling. Thus, it is not astonishing that sphingolipids and sphingolipid metabolism play a substantial role in inflammatory diseases that are modulated by DCs. Here we highlight the function of sphingosine 1-phosphate (S1P) on DC homeostasis and the role of SIP and SW metabolism in inflammatory diseases. KW - Sphingosine-1-phosphate KW - Dendritic cells KW - Fingolimod KW - IL-12 KW - Inflammation Y1 - 2014 U6 - https://doi.org/10.1159/000362982 SN - 1015-8987 SN - 1421-9778 VL - 34 IS - 1 SP - 27 EP - 44 PB - Karger CY - Basel ER - TY - CHAP A1 - Baranyai, Dorothea A1 - Goedtel-Armbrust, Ute A1 - Nestler, Sebastian A1 - Kleuser, Burkhard A1 - Wojnowski, Leszek T1 - A role for cutaneous CYP3A in vitamin D homeostasis? T2 - NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Y1 - 2014 SN - 0028-1298 SN - 1432-1912 VL - 387 SP - S27 EP - S27 PB - Springer CY - New York ER - TY - CHAP A1 - Arlt, Olga A1 - Schwiebs, Anja A1 - Pfarr, Kathrin A1 - Ranglack, Annika A1 - Bouzas, Ferreiros Nerea A1 - Schreiber, Yannick A1 - Neuber, Corinna A1 - Kleuser, Burkhard A1 - Pfeilschifter, Josef M. A1 - Radeke, Heinfried H. T1 - Dynamic interaction between sphingolipid enzymes, S1P and inflammatory cytokine regulation in dendritic cells T2 - NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Y1 - 2014 SN - 0028-1298 SN - 1432-1912 VL - 387 SP - S91 EP - S91 PB - Springer CY - New York ER - TY - JOUR A1 - Fayyaz, Susann A1 - Henkel, Janin A1 - Japtok, Lukasz A1 - Krämer, Stephanie A1 - Damm, Georg A1 - Seehofer, Daniel A1 - Püschel, Gerhard Paul A1 - Kleuser, Burkhard T1 - Involvement of sphingosine 1-phosphate in palmitate-induced insulin resistance of hepatocytes via the S1P(2) receptor subtype JF - Diabetologia : journal of the European Association for the Study of Diabetes (EASD) N2 - Enhanced plasma levels of NEFA have been shown to induce hepatic insulin resistance, which contributes to the development of type 2 diabetes. Indeed, sphingolipids can be formed via a de novo pathway from the saturated fatty acid palmitate and the amino acid serine. Besides ceramides, sphingosine 1-phosphate (S1P) has been identified as a major bioactive lipid mediator. Therefore, our aim was to investigate the generation and function of S1P in hepatic insulin resistance. The incorporation of palmitate into sphingolipids was performed by rapid-resolution liquid chromatography-MS/MS in primary human and rat hepatocytes. The influence of S1P and the involvement of S1P receptors in hepatic insulin resistance was examined in human and rat hepatocytes, as well as in New Zealand obese (NZO) mice. Palmitate induced an impressive formation of extra- and intracellular S1P in rat and human hepatocytes. An elevation of hepatic S1P levels was observed in NZO mice fed a high-fat diet. Once generated, S1P was able, similarly to palmitate, to counteract insulin signalling. The inhibitory effect of S1P was abolished in the presence of the S1P(2) receptor antagonist JTE-013 both in vitro and in vivo. In agreement with this, the immunomodulator FTY720-phosphate, which binds to all S1P receptors except S1P(2), was not able to inhibit insulin signalling. These data indicate that palmitate is metabolised by hepatocytes to S1P, which acts via stimulation of the S1P(2) receptor to impair insulin signalling. In particular, S1P(2) inhibition could be considered as a novel therapeutic target for the treatment of insulin resistance. KW - FTY720 KW - Insulin signalling KW - Palmitate KW - S1P receptors KW - Sphingolipids KW - Sphingosine 1-phosphate Y1 - 2014 U6 - https://doi.org/10.1007/s00125-013-3123-6 SN - 0012-186X SN - 1432-0428 VL - 57 IS - 2 SP - 373 EP - 382 PB - Springer CY - New York ER - TY - JOUR A1 - Sic, Heiko A1 - Kraus, Helene A1 - Madl, Josef A1 - Flittner, Karl-Andreas A1 - von Muenchow, Audrey Lilly A1 - Pieper, Kathrin A1 - Rizzi, Marta A1 - Kienzler, Anne-Kathrin A1 - Ayata, Korcan A1 - Rauer, Sebastian A1 - Kleuser, Burkhard A1 - Salzer, Ulrich A1 - Burger, Meike A1 - Zirlik, Katja A1 - Lougaris, Vassilios A1 - Plebani, Alessandro A1 - Roemer, Winfried A1 - Loeffler, Christoph A1 - Scaramuzza, Samantha A1 - Villa, Anna A1 - Noguchi, Emiko A1 - Grimbacher, Bodo A1 - Eibel, Hermann T1 - Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis JF - The journal of allergy and clinical immunology N2 - Background: Five different G protein-coupled sphingosine-1-phosphate (S1P) receptors (S1P1-S1P5) regulate a variety of physiologic and pathophysiologic processes, including lymphocyte circulation, multiple sclerosis (MS), and cancer. Although B-lymphocyte circulation plays an important role in these processes and is essential for normal immune responses, little is known about S1P receptors in human B cells. Objective: To explore their function and signaling, we studied B-cell lines and primary B cells from control subjects, patients with leukemia, patients with S1P receptor inhibitor-treated MS, and patients with primary immunodeficiencies. Methods: S1P receptor expression was analyzed by using multicolor immunofluorescence microscopy and quantitative PCR. Transwell assays were used to study cell migration. S1P receptor internalization was visualized by means of time-lapse imaging with fluorescent S1P receptor fusion proteins expressed by using lentiviral gene transfer. B-lymphocyte subsets were characterized by means of flow cytometry and immunofluorescence microscopy. Results: Showing that different B-cell populations express different combinations of S1P receptors, we found that S1P1 promotes migration, whereas S1P4 modulates and S1P2 inhibits S1P1 signals. Expression of CD69 in activated B lymphocytes and B cells from patients with chronic lymphocytic leukemia inhibited S1P-induced migration. Studying B-cell lines, normal B lymphocytes, and B cells from patients with primary immunodeficiencies, we identified Bruton tyrosine kinase, beta-arrestin 2, LPS-responsive beige-like anchor protein, dedicator of cytokinesis 8, and Wiskott-Aldrich syndrome protein as critical signaling components downstream of S1P1. Conclusion: Thus S1P receptor signaling regulates human B-cell circulation and might be a factor contributing to the pathology of MS, chronic lymphocytic leukemia, and primary immunodeficiencies. KW - Sphingosine-1-phosphate KW - B cells KW - migration KW - autoimmunity KW - circulation KW - fingolimod KW - FTY720 KW - primary immunodeficiencies Y1 - 2014 U6 - https://doi.org/10.1016/j.jaci.2014.01.037 SN - 0091-6749 SN - 1097-6825 VL - 134 IS - 2 SP - 420 EP - + PB - Elsevier CY - New York ER - TY - JOUR A1 - Pewzner-Jung, Yael A1 - Tabazavareh, Shaghayegh Tavakoli A1 - Grassme, Heike A1 - Becker, Katrin Anne A1 - Japtok, Lukasz A1 - Steinmann, Joerg A1 - Joseph, Tammar A1 - Lang, Stephan A1 - Tuemmler, Burkhard A1 - Schuchman, Edward H. A1 - Lentsch, Alex B. A1 - Kleuser, Burkhard A1 - Edwards, Michael J. A1 - Futerman, Anthony H. A1 - Gulbins, Erich T1 - Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa JF - EMBO molecular medicine N2 - Cystic fibrosis patients and patients with chronic obstructive pulmonary disease, trauma, burn wound, or patients requiring ventilation are susceptible to severe pulmonary infection by Pseudomonas aeruginosa. Physiological innate defense mechanisms against this pathogen, and their alterations in lung diseases, are for the most part unknown. We now demonstrate a role for the sphingoid long chain base, sphingosine, in determining susceptibility to lung infection by P.aeruginosa. Tracheal and bronchial sphingosine levels were significantly reduced in tissues from cystic fibrosis patients and from cystic fibrosis mouse models due to reduced activity of acid ceramidase, which generates sphingosine from ceramide. Inhalation of mice with sphingosine, with a sphingosine analog, FTY720, or with acid ceramidase rescued susceptible mice from infection. Our data suggest that luminal sphingosine in tracheal and bronchial epithelial cells prevents pulmonary P.aeruginosa infection in normal individuals, paving the way for novel therapeutic paradigms based on inhalation of acid ceramidase or of sphingoid long chain bases in lung infection. KW - cystic fibrosis KW - long chain base KW - lung infection KW - Pseudomonas aeruginosa KW - sphingosine Y1 - 2014 U6 - https://doi.org/10.15252/emmm.201404075 SN - 1757-4676 SN - 1757-4684 VL - 6 IS - 9 SP - 1205 EP - 1214 PB - Wiley-Blackwell CY - Hoboken ER - TY - JOUR A1 - Neuber, Corinna A1 - Schumacher, Fabian A1 - Gulbins, Erich A1 - Kleuser, Burkhard T1 - Method to simultaneously determine the sphingosine 1-phosphate breakdown product (2E)-hexadecenal and its fatty acid derivatives using isotope-dilution HPLC-electrospray ionization-quadrupole/time-of-flight mass spectrometry JF - Analytical chemistry N2 - Sphingosine 1-phosphate (S1P), a bioactive lipid involved in various physiological processes, can be irreversibly degraded by the membrane-bound S1P lyase (S1PL) yielding (2E)-hexadecenal and phosphoethanolamine. It is discussed that (2E)-hexadecenal is further oxidized to (2E)-hexadecenoic acid by the long-chain fatty aldehyde dehydrogenase ALDH3A2 (also known as FALDH) prior to activation via coupling to coenzyme A (CoA). Inhibition or defects in these enzymes, S1PL or FALDH, result in severe immunological disorders or the Sjogren-Larsson syndrome, respectively. Hence, it is of enormous importance to simultaneously determine the S1P breakdown product (2E)-hexadecenal and its fatty acid metabolites in biological samples. However, no method is available so far. Here, we present a sensitive and selective isotope-dilution high performance liquid chromatographyelectrospray ionizationquadrupole/time-of-flight mass spectrometry method for simultaneous quantification of (2E)-hexadecenal and its fatty acid metabolites following derivatization with 2-diphenylacetyl-1,3-indandione-1-hydrazone and 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide. Optimized conditions for sample derivatization, chromatographic separation, and MS/MS detection are presented as well as an extensive method validation. Finally, our method was successfully applied to biological samples. We found that (2E)-hexadecenal is almost quantitatively oxidized to (2E)-hexadecenoic acid, that is further activated as verified by cotreatment of HepG2 cell lysates with (2E)-hexadecenal and the acyl-CoA synthetase inhibitor triacsin C. Moreover, incubations of cell lysates with deuterated (2E)-hexadecenal revealed that no hexadecanoic acid is formed from the aldehyde. Thus, our method provides new insights into the sphingolipid metabolism and will be useful to investigate diseases known for abnormalities in long-chain fatty acid metabolism, e.g., the Sjogren-Larsson syndrome, in more detail. Y1 - 2014 U6 - https://doi.org/10.1021/ac501677y SN - 0003-2700 SN - 1520-6882 VL - 86 IS - 18 SP - 9065 EP - 9073 PB - American Chemical Society CY - Washington ER - TY - JOUR A1 - Imeri, Faik A1 - Fallegger, Daniel A1 - Zivkovic, Aleksandra A1 - Schwalm, Stephanie A1 - Enzmann, Gaby A1 - Blankenbach, Kira A1 - Heringdorf, Dagmar Meyer Zu A1 - Homann, Thomas A1 - Kleuser, Burkhard A1 - Pfeilschifter, Josef A1 - Engelhardt, Britta A1 - Stark, Holger A1 - Huwiler, Andrea T1 - Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice JF - Neuropharmacology N2 - The immunomodulatory FTY720 (fingolimod) is presently approved for the treatment of relapsing-remitting multiple sclerosis. It is a prodrug that acts by modulating sphingosine 1-phosphate (S1P) receptor signaling. In this study, we have developed and characterized two novel oxazolo-oxazole derivatives of FTY720, ST-968 and the oxy analog ST-1071, which require no preceding activating phosphorylation, and proved to be active in intact cells and triggered S1P(1) and S1P(3), but not S1P(2), receptor internalization as a result of receptor activation. Functionally, ST-968 and ST-1071 acted similar to FTY720 to abrogate S1P-triggered chemotaxis of mouse splenocytes, mouse T cells and human U937 cells, and reduced TNFa- and LPS-stimulated endothelial cell permeability. The compounds also reduced TNF alpha-induced ICAM-1 and VCAM-1 mRNA expression, but restored TNF alpha-mediated downregulation of PECAM-1 mRNA expression. In an in vivo setting, the application of ST-968 or ST-1071 to mice resulted in a reduction of blood lymphocytes and significantly reduced the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice comparable to FTY720 either by prophylactic or therapeutic treatment. In parallel to the reduced clinical symptoms, infiltration of immune cells in the brain was strongly reduced, and in isolated tissues of brain and spinal cord, the mRNA and protein expressions of ICAM-1 and VCAM-1, as well as of matrix metalloproteinase-9 were reduced by all compounds, whereas PECAM-1 and tissue inhibitor of metalloproteinase TIMP-1 were upregulated. In summary, the data suggest that these novel butterfly derivatives of FTY720 could have considerable implication for future therapies of multiple sclerosis and other autoimmune diseases. (C) 2014 Elsevier Ltd. All rights reserved. KW - Fingolimod KW - ST-968 KW - ST-1071 KW - Sphingosine 1-phosphate KW - Endothelial cells KW - Permeability KW - Multiple sclerosis Y1 - 2014 U6 - https://doi.org/10.1016/j.neuropharm.2014.05.012 SN - 0028-3908 SN - 1873-7064 VL - 85 SP - 314 EP - 327 PB - Elsevier CY - Oxford ER -